H.U. Group Holdings, Inc.
Change of Representative Executive Officer
Effective April 1, 2026, Mr. Takeshi Ishikawa will assume office as Representative Executive Officer President and Group CEO, while Mr. Narikazu Takeuchi will step down to Executive Director.
Key Figures
- New Representative Executive Officer President and Group CEO: Takeshi Ishikawa
- Outgoing Representative Executive Officer Chairman and President: Narikazu Takeuchi
- Scheduled appointment date: 2026-04-01
AI要約
Details of Change of Representative Executive Officer
At the Board of Directors meeting held on January 14, 2026, it was resolved that Mr. Takeshi Ishikawa will be appointed as Representative Executive Officer President and Group CEO. The current Representative Executive Officer Chairman and President, Mr. Narikazu Takeuchi, will step down to become an Executive Director. Mr. Ishikawa has contributed to the Group’s growth as the Executive Officer in charge of the In Vitro Diagnostics (IVD) business and has been selected as the successor to lead the execution of the medium-term management plan 'H.U. 2030'.
Background and Career of the New Representative Executive Officer
Born in 1976, Mr. Takeshi Ishikawa graduated from the University of Tokyo Faculty of Economics, joined the Defense Agency, completed Harvard Business School, worked at Boston Consulting Group, and joined our company in 2012. He has served as President of Fujirebio Inc. and, as of June 2025, is serving as Executive Managing Officer of our company. This appointment is based on the CEO succession plan and is scheduled to take effect officially on April 1, 2026.
